Individuation, Solid Tumor
Conditions
Brief summary
This study is an open, single center clinical study targeting solid tumor patients who have exhausted or cannot tolerate standard treatment regimens. The main purpose of this study is to investigate the feasibility, efficacy, and safety of selecting treatment regimens based on DOTr/DOTa results for solid tumor patients who have exhausted or cannot tolerate standard treatment regimens.
Detailed description
Both OncoTarget(DarwinOncoTargetTM (DOTa)), which identifies high-affinity inhibitors of individual master regulator (MR) proteins, and OncoTreat(DarwinOncoTreatTM (DOTr)), which identifies drugs that invert the transcriptional activity of hyperconnected MR modules, produced highly significant 30-day disease control rates (68% and 91%, respectively).
Interventions
OTHERRecommended treatment plan
Develop a final treatment plan based on DOTr/DOTA test results, MTB consultation expert opinions, and drug accessibility
Sponsors
Tianjin Medical University Second Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The subjects must be able to understand the procedures and methods of this study, be willing to strictly follow the clinical trial protocol to complete this trial, and voluntarily sign a written informed consent form; 2. Patients aged ≥ 18 years old; 3. Solid tumor patients who are depleted of standard treatment or unable to tolerate standard treatment regimens; 4. According to the RECIST solid tumor efficacy evaluation criteria, there should be at least one measurable lesion; 5. ECOG PS score 0-4 (3-4 score only for patients caused by tumor); 6. The expected survival period is not less than 12 weeks; 7. Women of childbearing age must have a Pregnancy test (serum) within 7 days before enrollment, and the result is negative, and are willing to use appropriate methods of contraception during the test period and within 8 weeks after the last administration of the test drug; 8. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up; 9. If the main organs function normally, they meet the following standards: The blood routine examination standard must comply with (no blood transfusion or blood products within 14 days, no correction using G-CSF or other hematopoietic stimulating factors): Hb ≥ 90g/L; ANC ≥ 1.5 × 109/L; PLT ≥ 90 × 109/L;Biochemical examination must meet the following standards: TBIL ≤ 1 × ULN; ALT, AST ≤ 1.5 × ULN; ALP ≤ 2.5 × ULN; BUN and Cr ≤ 1.5 × ULN; Color Doppler echocardiography: left ventricular Ejection fraction (LVEF) ≥ 50%.
Exclusion criteria
1. Severe heart disease or discomfort that cannot be treated; 2. Those who suffer from mental illness or abuse of psychotropic substances and are unable to cooperate; 3. Pregnant or lactating female patients; 4. Participating in other clinical trials at the same time; 5. Researchers believe that individuals are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of selecting treatment plans based on DOTr/DOTA result | Through study completion, an expected average of 2year | The proportion of patients who successfully develop treatment plans based on DOTr and DOTa test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ORR | Through study completion, an expected average of 1 year | Objective response rate (ORR) based on RECIST 1.1 criteria for patients receiving recommended treatment regimens |
| PFS2/PFS1 | Through study completion, an expected average of 1 year | he progression free survival (PFS1) after the most recent treatment before enrollment is defined as the progression of the disease from the most recent treatment before enrollment; The progression free survival period (PFS2) after enrollment is defined as the time from matched targeted therapy or unmatched therapy to disease progression or death |
| AEs | Through study completion, an expected average of 1 year | Number of participants with adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 |
Countries
China
Contacts
Primary ContactHaiTao Wang, Ph.D
Backup ContactLili Wang, Ph.D
Outcome results
None listed